Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tilray Brands Inc TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Bullboard Posts
Post by RadientTechon Oct 12, 2018 10:23am
66 Views
Post# 28787834

Aphria and TBP will be bought out together

Aphria and TBP will be bought out together

Carl Merton recently commented on the link between TBP and APH.

"We maintain a strong relationship with TBP. In addition, to being a member of their board of directors, including Chair of the Audit Committee, and Aphria being a large shareholder, we maintain a supply contract with TBP for two products which they are performing clinical trials on – PPP001, a compressed dried flower product that is smoked, and PPP005 – an oil based product that is delivered with a syringe in the mouth.

Tetra has many interesting trials going on currently, including a recent announcement of a head-to-head study on pain management for PPP001 against Fentanyl. In addition to the Fentanyl study, PPP001 is currently in Phase 3, with the end goal being a DIN. We see enormous opportunity for our relationship with Tetra, both as a supplier and as a shareholder.

The interesting part about clinical drug trials is that once you start a trial with an active ingredient, you can’t change it without a 5-year bridging study. The bridging study is done to prove that the new active ingredient is composed of the exact same molecules and has the exact same affects as the original active ingredient. 5 years is a long time to slow your clinical study. I think it is also important to appreciate that the active ingredient we created for TBP is composed of a proprietary blend of 3 different varieties, making it even more difficult to duplicate."

This statement shows that neither company will be able to operate without the other, in order to penetrate the pharmaceutical marijuana market. They rely on each other for either the supply of the ingredient, or the pharmaceutical clinical trials; both are required, but both are owned by separate companies. A supply agreement is what makes this relationship work (beyond an investment from APH into TBP).

Therefore, if any large pharmaceutical company wants to buy TBP, they must buy APH too, to get the whole product.

Bullboard Posts